Abstract
BackgroundSeveral studies suggested that thrombotic and obstetric antiphospholipid syndromes could be independent identities, but few have systematically compared their clinical characteristics and prognosis.ObjectiveThe objective of this study is to identify key differences between thrombotic APS (tAPS) and obstetric APS (oAPS).MethodsThis single-center, prospective study included consecutive patients with primary antiphospholipid syndrome (APS) receiving treatment at the Peking Union Medical College Hospital during a period from 2013 to 2020.ResultsScreening of the database yielded a total of 244 women with positive antiphospholipid antibody (aPL). Among the 105 women with primary APS, 39 (37.14%) had isolated tAPS (ItAPS), 44 (41.90%) had isolated oAPS (IoAPS), and 9 (8.57%) had both tAPS and tAPS+oAPS. In comparison to those with IoAPS, patients with ItAPS had older age (41.92 ± 11.97 vs. 33.16 ± 4.22 years, P < 0.01), higher rate of cardiovascular risk (at least one positive of coronary heart disease, hypertension, obesity, diabetes, and hyperlipidemia) (41.03% vs. 6.82%, P < 0.01), and higher frequency of thrombocytopenia (43.59% vs. 20.45%, P < 0.05). Antibody profiles were generally similar among the groups, but isolated anti-β2GPI positivity was more common in patients with IoAPS (52.27% vs. 17.94% for ItAPS, P = 0.01). Triple aPL positivity was more common in patients with both tAPS and oAPS (66.67% vs. 46.15% for ItAPS vs. 25% for IoAPS, P = 0.022). Blood homocysteine was higher in patients with ItAPS (11.20 vs. 9.90 μmol/L for IoAPS, P < 0.05), but there were no differences in inflammatory markers or complements. Recurrence rate of thrombosis was higher in patients with ItAPS (33.33% vs. 2.27% for IoAPS, P ≤ 0.001) with a mean follow-up of 61 months.ConclusionDespite generally similar antibody and biochemical profiles, patients with ItAPS had much higher risk of recurrent thrombosis than IoAPS, supporting distinct mechanisms of pathogenesis.
Highlights
Based on the 2006 revised Sydney criteria, antiphospholipid syndrome (APS) is defined as prolonged positive of antiphospholipid antibody with thrombotic and/or obstetric manifestations
Demographics and baseline laboratory results The database included a total of 244 patients with persistent positive Antiphospholipid antibodies (aPLs)
13 (12.38%) had isolated Thrombotic APS (tAPS) (ItAPS) but no history of pregnancy, 39 (37.14%) had ItAPS and pregnancy histories, 44 (41.90%) had isolated obstetric APS (oAPS) (IoAPS), and 9 (8.57%) had both tAPS and oAPS (Fig. 1)
Summary
Based on the 2006 revised Sydney criteria, antiphospholipid syndrome (APS) is defined as prolonged positive of antiphospholipid antibody (aPL) with thrombotic and/or obstetric manifestations. Thrombotic APS (tAPS) and obstetric APS (oAPS) share similar antibody profiles and manifestations, but may represent distinct diseases [3,4,5]. We conducted a longitudinal study to compare clinical characteristics and antibody profiles in patients with isolated tAPS (ItAPS) vs isolated oAPS (IoAPS). The adjusted Global AntiPhospholipid Syndrome Score (aGAPSS) conceived by Savino Sciascia et al was used to assess thrombotic risk, combing cardiovascular risks and aPL positivity [7, 8]. Several studies suggested that thrombotic and obstetric antiphospholipid syndromes could be independent identities, but few have systematically compared their clinical characteristics and prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
